Jupiter Neurosciences has initiated Phase 2a enrollment for JOTROL, an oral resveratrol formulation designed to address underlying neurodegeneration in Parkinson's disease rather than managing symptoms alone. The candidate demonstrates nine-fold higher bioavailability than conventional resveratrol and crosses the blood-brain barrier, targeting mitochondrial dysfunction, inflammation, and oxidative stress at the cellular level.
Key Points
- JOTROL targets mitochondrial dysfunction and oxidative stress, not dopamine replacement
- Micellar formulation achieves 9x higher bioavailability than standard resveratrol
- Measurable cerebrospinal fluid levels confirm central nervous system penetration
Longevity Analysis
Parkinson's represents a systems-level failure—mitochondrial energy production falters, inflammation persists unchecked, and neurons deteriorate under oxidative stress. This approach moves beyond symptomatic management to address the aging-related processes driving cellular vulnerability. By improving bioavailability and enabling sustained brain exposure, JOTROL targets the conditions that allow neurons to function despite mounting internal damage. The strategy reflects a fundamental shift in neuroscience: treating the disease's foundation rather than its surface manifestations aligns with how longevity science now frames age-related diseases as problems of accumulated cellular stress and failed adaptation.
Original published by Longevity.Technology, by Kyle Umipig.